Zarmeena Vendal, MD
Ophthalmology · West Lake Hills, TXNPI 1770534737
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $257,185 of the $404,353 with a category attached, or 63.6%. 27 manufacturers reported payments, led by Alcon at 51.5% of the total. 2025 is the largest year on record at $134,616, more than ten times the $3,711 reported in 2019. Among ophthalmology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 688 payments — averaging $587.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$208K
- Sight Sciences, Inc.$66K
- AbbVie$46K
- Alcon Research LLC$28K
- Biotissue Holdings Inc.$22K
- Bausch & Lomb Americas Inc.$17K
- plus $17K from 21 others
Across 23 payments — averaging $15,928 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$162K
- Johnson & Johnson Surgical Vision, Inc.$99K
- Biotissue Holdings Inc.$63K
- Rxsight Inc$42K
What the payments were for
- Consulting fees$257,18564%
- Speaking & faculty fees$105,37526%
- Travel & lodging$19,7195%
- Food & beverage$22,0755%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 251 | $208,422 |
| Sight Sciences, Inc. | 68 | $65,626 |
| AbbVie(2 entities) | 123 | $46,272 |
| Alcon Research LLC | 13 | $28,169 |
| Biotissue Holdings Inc. | 38 | $21,923 |
| Bausch & Lomb Americas Inc. | 38 | $16,627 |
| Glaukos Corporation | 12 | $5,843 |
| Rxsight Inc | 15 | $4,671 |
| Johnson & Johnson Surgical Vision, Inc. | 32 | $4,632 |
| Sun Pharmaceutical Industries Inc. | 19 | $472 |
| Ocular Therapeutix, Inc. | 15 | $314 |
| Aerie Pharmaceuticals, Inc. | 11 | $223 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 12 | $202 |
| Amgen(2 entities) | 8 | $152 |
| Thea Pharma Inc. | 6 | $128 |
| Novartis | 6 | $119 |
| Ivantis, Inc | 2 | $116 |
| Eyevance Pharmaceuticals LLC | 4 | $73 |
| Oyster Point Pharma, Inc. | 3 | $69 |
| Shire North American Group Inc | 3 | $64 |
| Tearlab Corp | 3 | $58 |
| Beaver-visitec International, Inc. | 1 | $36 |
| Dompe US, Inc. | 1 | $32 |
| ANI Pharmaceuticals, Inc. | 1 | $31 |
| Astellas Pharma US Inc | 1 | $27 |
| Harrow Eye, LLC | 1 | $26 |
| NEW World Medical,inc. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OMNI(R) SURGICAL SYSTEM (US)$63,735
- Hydrus Microstent$50,151
- Clareon$42,142
- DURYSTA$40,372
- LenSx$35,796
- SION SURGICAL INSTRUMENT$30,355
- AcrySof IQ PanOptix UV IOL$21,680
- NGENUITY$21,050
- AcrySof IQ VIVITY$16,030
- Rhopressa$15,419
- AcrySof IQ VIVITY IOL$14,633
- AcrySof IQ PanOptix$11,471
- Voyager DSLT$9,650
- Clareon PanOptix Pro$7,625
- Prokera$6,298
- AmnioGraft$6,298
- AmnioGuard$6,175
- Luxor$5,803
- Rocklatan$5,779
- VYZULTA$4,788
How this compares
$404,353 in reported general payments places this provider in the 95th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 294 | $160,322 |
| RocklatanNetarsudil Mesylat/Latanoprost | 169 | $65,350 |
| RhopressaNetarsudil Mesylate | 164 | $59,688 |
| RestasisCyclosporine | 36 | $48,378 |
| CombiganBrimonidine Tartrate/Timolol | 85 | $32,157 |
| Brimonidine Tartrate | 157 | $25,317 |
| Alphagan PBrimonidine Tartrate | 59 | $25,056 |
| VyzultaLatanoprostene Bunod | 47 | $24,796 |
| XiidraLifitegrast | 12 | $20,143 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 99 | $17,769 |
| Cyclosporine | 26 | $9,443 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 44 | $9,104 |
| Latanoprost | 619 | $7,563 |
| Bromfenac Sodium | 37 | $5,172 |
| Travoprost | 36 | $5,157 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $46,272 | $265,913474 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $223 | $125,038333 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $16,627 | $44,93959 claims |
| AlconSimbrinza | $208,422 | $9,10444 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in West Lake Hills
- Michael SingerSan Antonio$1.8M
- Oluwatosin SmithDallas$1.5M
- Charles WykoffBellaire$1.5M
- John MichelettiHouston$916K
- Davinder GroverDallas$705K
- Christina WengHouston$676K
- Peter ChangHouston$656K
- Zaina Al-MohtasebHouston$636K
- Ashkan AbbeyDallas$559K
- Stephen SladeHouston$530K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.